IL161005A0 - Neuroprotective treatment methods using selective inos inhibitors - Google Patents

Neuroprotective treatment methods using selective inos inhibitors

Info

Publication number
IL161005A0
IL161005A0 IL16100502A IL16100502A IL161005A0 IL 161005 A0 IL161005 A0 IL 161005A0 IL 16100502 A IL16100502 A IL 16100502A IL 16100502 A IL16100502 A IL 16100502A IL 161005 A0 IL161005 A0 IL 161005A0
Authority
IL
Israel
Prior art keywords
treatment methods
inos inhibitors
neuroprotective treatment
selective inos
selective
Prior art date
Application number
IL16100502A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of IL161005A0 publication Critical patent/IL161005A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16100502A 2001-09-24 2002-09-24 Neuroprotective treatment methods using selective inos inhibitors IL161005A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/961,521 US20030119826A1 (en) 2001-09-24 2001-09-24 Neuroprotective treatment methods using selective iNOS inhibitors
PCT/US2002/030214 WO2003026638A1 (en) 2001-09-24 2002-09-24 Neuroprotective treatment methods using selective inos inhibitors

Publications (1)

Publication Number Publication Date
IL161005A0 true IL161005A0 (en) 2004-08-31

Family

ID=25504581

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16100502A IL161005A0 (en) 2001-09-24 2002-09-24 Neuroprotective treatment methods using selective inos inhibitors

Country Status (13)

Country Link
US (1) US20030119826A1 (xx)
EP (1) EP1429752A1 (xx)
JP (1) JP2005508910A (xx)
KR (1) KR20040039394A (xx)
CN (1) CN1556698A (xx)
AU (1) AU2002327042A2 (xx)
BR (1) BR0212989A (xx)
CA (1) CA2455989A1 (xx)
IL (1) IL161005A0 (xx)
MX (1) MXPA04002710A (xx)
PL (1) PL371774A1 (xx)
WO (1) WO2003026638A1 (xx)
ZA (1) ZA200402288B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
CA2625287C (en) * 2005-10-19 2016-07-26 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
ZA200810790B (en) * 2006-06-12 2010-03-31 Teva Pharma Stable laquinimod preparations
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
KR20160079147A (ko) * 2008-09-03 2016-07-05 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 2―옥소―1,2―다이하이드로―퀴놀린 조절제
MX2012001333A (es) * 2009-07-30 2012-06-01 Teva Pharma Tratamiento de la enfermedad de crohn con la laquinimod.
ES2586843T3 (es) * 2009-08-10 2016-10-19 Teva Pharmaceutical Industries Ltd. Tratamiento de trastornos relacionados con BDNF usando laquinimod
MX2014004420A (es) 2011-10-12 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod.
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
KR20150091077A (ko) 2012-11-07 2015-08-07 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드의 아민염
AU2014236232A1 (en) 2013-03-14 2015-11-05 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60110902T2 (de) * 2000-03-24 2006-04-27 Pharmacia Corp., Chicago Amidino-verbindung sowie salze davon verwendbar als hemmstoffe der stickstoffmonoxid-synthase
AR032318A1 (es) * 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa

Also Published As

Publication number Publication date
CN1556698A (zh) 2004-12-22
WO2003026638A1 (en) 2003-04-03
KR20040039394A (ko) 2004-05-10
US20030119826A1 (en) 2003-06-26
JP2005508910A (ja) 2005-04-07
ZA200402288B (en) 2006-12-27
MXPA04002710A (es) 2004-07-05
BR0212989A (pt) 2005-04-26
AU2002327042A2 (en) 2003-04-07
CA2455989A1 (en) 2003-04-03
EP1429752A1 (en) 2004-06-23
PL371774A1 (en) 2005-06-27

Similar Documents

Publication Publication Date Title
EP1361604A4 (en) DEVICE AND METHOD OF TREATMENT
IL213240A0 (en) Method of treatment using lighnd-immunogen conjugates
EP1408862A4 (en) ABLATION PROCESSES AND DEVICES
GB0115980D0 (en) Apparatus and methods
EP1365446A4 (en) PLASMA PROCESSING DEVICE AND PROCESS
GB0129976D0 (en) Treatment method
GB0118383D0 (en) Therapeutic methods
IL161005A0 (en) Neuroprotective treatment methods using selective inos inhibitors
EP1535577A4 (en) LIGA TION TREATMENT UNIT
GB0120147D0 (en) Treatment method
GB0101244D0 (en) Process and apparatus
SG89379A1 (en) Treatment apparatus
GB0130763D0 (en) Treatment methods
GB0026838D0 (en) Treatment method
IL161004A0 (en) Ophthalmologic treatment methods using selective inos inhibitors
GB0031321D0 (en) Treatment
EP1303281A4 (en) METHODS OF TREATMENT
GB0104555D0 (en) New Therapeutic method
GB0126253D0 (en) Treatment method
GB0130694D0 (en) Treatment
GB0102927D0 (en) Treatment method
GB0109519D0 (en) Nimico treatment
GB0116837D0 (en) Treatment
SI1377249T1 (sl) Priprava za akupunkturno terapijo
GB0112689D0 (en) Dispenser and treatment means